Literature DB >> 21909131

Activation of tumor cell proliferation by thyroid hormone in a mouse model of follicular thyroid carcinoma.

C Lu1, X Zhu, M C Willingham, S-Y Cheng.   

Abstract

Thyroid cancers are the most common malignancy of the endocrine system in humans. To understand the molecular genetic events underlying thyroid carcinogenesis, we have generated a mouse model that spontaneously develops follicular thyroid carcinoma similar to human thyroid cancer (Thrb(PV/PV) mouse). This mutant mouse harbors a dominant-negative mutated thyroid hormone receptor β (denoted PV). The PV mutation was identified in a patient with resistance to thyroid hormone (TH). Thrb(PV/PV) mice exhibit highly elevated serum thyroid-stimulating hormone levels and increased TH. We have previously shown that thyroid-stimulating hormone is required, but not sufficient to induce metastatic follicular thyroid cancer in Thrb(PV/PV) mice. However, whether the elevated TH also contributes to the thyroid carcinogenesis of Thrb(PV/PV) mice was not elucidated. To understand the role of TH in thyroid carcinogenesis, we blocked the production of TH by treating Thrb(PV/PV) mice with propylthiouracil (Thrb(PV/PV)-PTU mice) and compared the development of thyroid cancer in Thrb(PV/PV)-PTU and untreated Thrb(PV/PV) mice. We found that thyroid tumor growth was reduced by ∼42% in Thrb(PV/PV)-PTU mice as compared with Thrb(PV/PV) mice. Analysis by bromodeoxyuridine-nuclear labeling showed decreased incorporation of bromodeoxyuridine in thyroid tumor cells of Thrb(PV/PV)-PTU mice, indicative of decreased tumor cell proliferation. However, cleaved-caspase 3 staining showed no apparent changes in apoptosis of tumor cells in Thrb(PV/PV)-PTU mice. Molecular studies identified a marked attenuation of the PI3K-AKT-β-catenin signaling pathway that led to decreased protein levels of cyclin D2, thereby decreasing tumor cell proliferation in Thrb(PV/PV)-PTU mice. Furthermore, matrix metalloproteinase-2, a downstream target of β-catenin and a key regulator during tumor invasion and metastasis, was also decreased. Thus, the present study uncovers a critical role of TH in promoting the thyroid carcinogenesis of Thrb(PV/PV) mice via membrane signaling events. Importantly, these findings suggest that anti-thyroid drugs could be considered as possible therapeutic agents of thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21909131      PMCID: PMC3728834          DOI: 10.1038/onc.2011.390

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  50 in total

1.  Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer.

Authors:  K Boelaert; C J McCabe; L A Tannahill; N J L Gittoes; R L Holder; J C Watkinson; A R Bradwell; M C Sheppard; J A Franklyn
Journal:  J Clin Endocrinol Metab       Date:  2003-05       Impact factor: 5.958

Review 2.  Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas.

Authors:  Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

3.  Tumor suppressor action of liganded thyroid hormone receptor beta by direct repression of beta-catenin gene expression.

Authors:  Celine J Guigon; Dong Wook Kim; Xuguang Zhu; Li Zhao; Sheue-yann Cheng
Journal:  Endocrinology       Date:  2010-09-15       Impact factor: 4.736

4.  Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.

Authors:  Peng Hou; Dingxie Liu; Yuan Shan; Shuiying Hu; Kimberley Studeman; Stephen Condouris; Yangang Wang; Ariel Trink; Adel K El-Naggar; Giovanni Tallini; Vasily Vasko; Mingzhao Xing
Journal:  Clin Cancer Res       Date:  2007-02-15       Impact factor: 12.531

5.  Thyroid cancer: is the incidence rise abating?

Authors:  Geneviève Sassolas; Zakia Hafdi-Nejjari; Laurent Remontet; Nadine Bossard; Aurélien Belot; Nicole Berger-Dutrieux; Myriam Decaussin-Petrucci; Claire Bournaud; Jean Louis Peix; Jacques Orgiazzi; Françoise Borson-Chazot
Journal:  Eur J Endocrinol       Date:  2008-10-24       Impact factor: 6.664

Review 6.  Molecular aspects of thyroid hormone actions.

Authors:  Sheue-Yann Cheng; Jack L Leonard; Paul J Davis
Journal:  Endocr Rev       Date:  2010-01-05       Impact factor: 19.871

Review 7.  Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression.

Authors:  Jiyong Liang; Joyce M Slingerland
Journal:  Cell Cycle       Date:  2003 Jul-Aug       Impact factor: 4.534

Review 8.  Beta-catenin and cyclin D1: connecting development to breast cancer.

Authors:  Tracey M Rowlands; Irina V Pechenkina; Sarah Hatsell; Pamela Cowin
Journal:  Cell Cycle       Date:  2004-02       Impact factor: 4.534

9.  L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase.

Authors:  Hung-Yun Lin; Mingzeng Sun; Heng-Yuan Tang; Cassie Lin; Mary K Luidens; Shaker A Mousa; Sandra Incerpi; George L Drusano; Faith B Davis; Paul J Davis
Journal:  Am J Physiol Cell Physiol       Date:  2009-01-21       Impact factor: 4.249

10.  Thyroid hormone is a MAPK-dependent growth factor for thyroid cancer cells and is anti-apoptotic.

Authors:  Hung-Yun Lin; Heng-Yuan Tang; Ai Shih; Travis Keating; Gary Cao; Paul J Davis; Faith B Davis
Journal:  Steroids       Date:  2006-12-15       Impact factor: 2.760

View more
  10 in total

1.  Thyroid-specific ablation of the Carney complex gene, PRKAR1A, results in hyperthyroidism and follicular thyroid cancer.

Authors:  Daphne R Pringle; Zhirong Yin; Audrey A Lee; Parmeet K Manchanda; Lianbo Yu; Alfred F Parlow; David Jarjoura; Krista M D La Perle; Lawrence S Kirschner
Journal:  Endocr Relat Cancer       Date:  2012-05-24       Impact factor: 5.678

2.  Common tumor-suppressive signaling of thyroid hormone receptor beta in breast and thyroid cancer cells.

Authors:  Eric L Bolf; Noelle E Gillis; Cole D Davidson; Lauren M Cozzens; Sophie Kogut; Jennifer A Tomczak; Seth Frietze; Frances E Carr
Journal:  Mol Carcinog       Date:  2021-09-17       Impact factor: 4.784

Review 3.  Molecular pathogenesis and mechanisms of thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Nat Rev Cancer       Date:  2013-03       Impact factor: 60.716

Review 4.  Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF.

Authors:  Z A Antonello; C Nucera
Journal:  Oncogene       Date:  2013-12-23       Impact factor: 9.867

5.  Three-dimensional telomere dynamics in follicular thyroid cancer.

Authors:  Landon Wark; Adrian Danescu; Suchitra Natarajan; Xuguang Zhu; Sheue-yann Cheng; Sabine Hombach-Klonisch; Sabine Mai; Thomas Klonisch
Journal:  Thyroid       Date:  2013-09-04       Impact factor: 6.568

6.  CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse model.

Authors:  Y Ward; R Lake; P L Martin; K Killian; P Salerno; T Wang; P Meltzer; M Merino; S-y Cheng; M Santoro; G Garcia-Rostan; K Kelly
Journal:  Oncogene       Date:  2012-07-16       Impact factor: 9.867

7.  Role of the wnt pathway in thyroid cancer.

Authors:  Ana Sastre-Perona; Pilar Santisteban
Journal:  Front Endocrinol (Lausanne)       Date:  2012-02-29       Impact factor: 5.555

Review 8.  Molecular Functions of Thyroid Hormone Signaling in Regulation of Cancer Progression and Anti-Apoptosis.

Authors:  Yu-Chin Liu; Chau-Ting Yeh; Kwang-Huei Lin
Journal:  Int J Mol Sci       Date:  2019-10-09       Impact factor: 5.923

9.  Thyroid Hormone Receptor β Suppression of RUNX2 Is Mediated by Brahma-Related Gene 1-Dependent Chromatin Remodeling.

Authors:  Noelle E Gillis; Thomas H Taber; Eric L Bolf; Caitlin M Beaudet; Jennifer A Tomczak; Jeffrey H White; Janet L Stein; Gary S Stein; Jane B Lian; Seth Frietze; Frances E Carr
Journal:  Endocrinology       Date:  2018-06-01       Impact factor: 4.736

Review 10.  Wnt Signaling in Thyroid Homeostasis and Carcinogenesis.

Authors:  Kim A Ely; Lindsay A Bischoff; Vivian L Weiss
Journal:  Genes (Basel)       Date:  2018-04-10       Impact factor: 4.096

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.